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Individuals suﬀering from human immunodeﬁciency virus type 1 (HIV-1) infection suﬀer from a wide range of neurological
deﬁcits. The most pronounced are the motor and cognitive deﬁcits observed in many patients in the latter stages of HIV infec-
tion. Gross postmortem inspection shows cortical atrophy and widespread neuronal loss. One of the more debilitating of the
HIV-related syndromes is AIDS-related dementia, or HAD. Complete understanding of HIV neurotoxicity has been elusive. Both
direct and indirect toxic mechanisms have been implicated in the neurotoxicity of the HIV proteins, Tat and gp120. The gluta-
matergic system, nitric oxide, calcium, oxidative stress, apoptosis, and microglia have all been implicated in the pathogenesis of
HIV-related neuronal degeneration. The aim of this review is to summarize the most recent work and provide an overview to the
current theories of HIV-related neurotoxicity and potential avenues of therapeutic interventions to prevent the neuronal loss and
motor/cognitive deﬁcits previously described.
Copyright © 2006 David R. Wallace. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
GENERAL MECHANISMS OF HIV NEUROTOXICITY
Just over a decade ago, the ﬁrst reports of HIV-related neu-
rotoxicity were published. Two proteins associated with the
AIDS virus, gp120 (a coat glycoprotein) and Tat (trans-
activation) have been shown to be neurotoxic. The HIV-
associated protein gp120 was shown to be neurotoxic to cul-
tured dopamine neurons [1]. Exposure to gp120 for 3 days
reduced the ability of neurons to transport dopamine and
decreased the size of the dendritic tree. The neurotoxicity of
Tat was ﬁrst identiﬁed by Nath et al [2] when they described
the reactive epitope of Tat as being Tat31–61. Full-length Tat is
86–104 amino acids in length and the analysis of peptides of
diﬀering, overlapping, lengths did not yield toxic responses
in primary neuronal culture. Shortly after this report, Cheng
et al [3] reported that Tat was neurotoxic to fetal neurons
through a calcium-dependent mechanism. One postulated
mechanism for Tat toxicity is via increased oxidative stress.
DirectintrastriatalinjectionsofTatresultsinasigniﬁcantin-
crease in carbonyl formation [4]. Increased gliosis has been
observed, indicating neuronal death and inﬁltration by glia
[4–6]. Cellular damage and death following Tat administra-
tion have also been linked to an increase in apoptosis [7, 8].
Other mechanisms for Tat neurotoxicity include altered cal-
cium homeostasis [7, 9], stimulation of TNF-α and NF-κB
[10], stimulation of glutamate receptors [11], and activation
of nitric oxide synthase and stimulation of nitric oxide pro-
duction [12]. Similar to Tat, gp120 has been shown to be
neurotoxic via multiple pathways. Both in vivo and in vitro,
gp120 administration has been shown to induce apoptosis
[13, 14]. Antagonism of glutamate receptors, primarily the
NMDA subtype, attenuates gp120-induced toxicity [11, 15].
Activation and stimulation of the nitric oxide synthesis path-
ways has also been reported following exposure to gp120
[15].
Biomarkers of oxidative stress have consistently been de-
tectedinbraintissuesandcerebrospinalﬂuidofpatientswith
HIV-associated dementia [16]. The role for HIV-1 proteins
in the development of oxidative stress associated with HIV-
1 infection was proposed [17]. It is still debated whether
the oxidative stress in HIV is attributable to direct interac-
tions of HIV-1 proteins with neural cells or whether it results
from chronic inﬂammatory reaction induced by the expo-
sure of the CNS tissue to virotoxins. However, it is evident
that neurotoxic HIV-1 proteins released from cells harbor-
ing HIV-1 may directly trigger oxidative stress, both in cell
culture [7, 18] and in animal models [4, 6]. Even a tran-
sient exposure to HIV-1 proteins may be suﬃcient to trig-
ger a cascade of events that leads to neuronal degeneration
[19]. Thus, Tat is an important mediator of neurotoxicity in
the HIV-infected brain and investigation of its role in HIV-
associated neurodegeneration is important for understand-
ing of the pathogenesis of HIV cognitive and motor dysfunc-
tion.2 Journal of Biomedicine and Biotechnology
MICROGLIA/ASTROCYTES AND OPIOIDS
Involvement of microglia and astrocytes in HIV-related neu-
rotoxicity has been established. Yet, whether the eﬀects ob-
served due to microglia involvement are a direct result of
HIV-1 stimulation or a byproduct of infection remains to be
elucidated.Parallelscanbedrawnbetweenmicrogliainvolve-
ment in neurological disorders such as HIV-related demen-
tia, multiple sclerosis, and Alzheimer’s disease [20]. In each
disorder, microglia involvement includes the inﬂammatory
process and the release of cytokines, chemokines, and nitric
oxide.Inadditiontothereleaseofdamagingchemokinesand
cytokines, the tumor suppressor transcription factor, p53,
has been shown to be necessary to induce apoptosis [21].
This could provide a novel pathway for HIV induction of
neuronal apoptosis and cell death. A quite diﬀerent proﬁle is
observed with astrocytes. When astrocytes express Tat, sur-
vival is promoted via increased antioxidant mechanisms, but
Tat is released into the extracellular space where the adjacent
neurons can take up Tat where axonal transport can take it
to distal sites where it will elicit toxic eﬀects [22, 23]. As neu-
rons die, reactive gliosis takes place. This is characterized by
an increase in glial ﬁbrillary acidic protein (GFAP) staining.
An increase in GFAP staining has been reported in cells ex-
posed to Tat [24]. Astrocytosis could be particularly relevant
in individuals abusing intravenous drugs. Astrocytes express
opioid receptors and stimulation of the mu-subtype of the
opioidreceptorfamilypotentiatesTattoxicityinneuronsand
astrocytes[25].In addition to intravenous drug use,stimula-
tion of mu-opioid receptors acting synergistically with HIV
proteins to elicit neurodegeneration has greater impact re-
garding the use of opioid analgesics for the relief of pain. The
use of morphine, codeine, fentanyl, and so forth, would be
prohibitiveinpatientsaﬄictedwithHIVduetotheincreased
risk for synergistic toxicity. Administration of morphine has
been shown to upregulate the expression of the CCR3 core-
ceptor and CCR5 receptor in astrocytoma cells, which would
increase viral binding and traﬃcking of the virus and pro-
mote viral infection [26]. Collectively, mu-stimulating opi-
oid ligands would increase the receptors necessary for the
transmission of the virus (CCR3 and CCR5), and poten-
tiate the neurotoxicity observed in the presence of gp120.
Recently, investigations into other opioid subtype-selective
(kappa and delta) and their possible functionality as thera-
peutic interventions have begun (refer to “potential thera-
peutic interventions”). The role of astrocytes and microglia
inthepathogenesisofHIV-relatedneurotoxicityisbecoming
increasingly apparent. From harboring the virus, to secreting
proinﬂammatory chemokines and cytokines, to potentiating
the spread of the virus and the viral particles, astrocytes and
microglia play an integral role in HIV-related neurotoxicity.
CHEMOKINES
Proinﬂammatory chemokines function to exacerbate HIV
neurotoxicity as an extension of astrocytes and microglia
function. Chemokine involvement has long been suspected
due to the actions of microglia following exposure to HIV-
related proteins. The two prominent chemokine receptors
that are involved in HIV neurotoxicity are the CXCR4 and
CCR5 receptors, both of which are expressed on microglia
[27]. The CXCR4 receptor belongs to the family of G-
protein-coupled receptors and is believed to signal through
a Gi/Go mechanism. Stimulation of these receptors results in
an elevation in intracellular calcium, an eﬀect which is re-
duced when pretreated with pertussis toxin to inactivate the
receptor [28]. Initial hypotheses included gp120 direct in-
teractions with neurons resulting in apoptosis, stimulation
of astrocytes/microglia resulting in indirect eﬀects on neu-
rons, or possibly both mechanisms. Apoptosis induced by
gp120 can be completely attenuated in the presence of the
tripeptide, TKP, which prevents activation of microglia via
CXCR4 receptors [29]. Antibodies to CXCR4 also prevented
neuronalapoptosisduetocaspase-3activation[30].Interest-
ingly, the density of the CXCR4 receptor is inversely related
to the concentration of ﬁbroblast growth factor (FGF). As
concentrations of FGF are increased, the density of CXCR4
r e c e p t o r si sr e d u c e d[ 31]. These eﬀe c t sa r en o td u et od i -
rect actions of FGF on CXCR4 receptors, but through the
FGF receptor kinase signaling pathway. Inhibitors of FGF
receptor kinase attenuate the eﬀects of FGF on CXCR4 re-
ceptor density [31]. Collectively, the eﬀects of FGF in HIV
encephalitis may be mediated through the inverse regu-
lation of CXCR4 receptor expression. Similarly, stimula-
tion of CHP100 cells, which constitutively express CXCR4
and CCR5 receptors, with phorbol 12-myristate-13-acetate
downregulates CXCR4 and CCR5 and decreases the extent
of gp120-induced cell death [32]. Alpha and beta chemokine
ligands which are naturally released from microglia and as-
trocytessuchasSDF1alpha,MIP1alpha,MIP1beta,and“reg-
ulated on activation, normal T-cell expressed and secreted”
(RANTES) all interfere with the action of gp120 at CXCR4
and CCR5 receptors, and thus reduce cellular apoptosis and
death [29, 30, 32]. SDF-1 results in a rapid release of tumor
necrosis factor-alpha (TNF-alpha), which in turn exerts au-
tocrine and paracrine eﬀects on nearby cells. The release of
TNF-alpha increases the synthesis of prostaglandins by ac-
tivating the arachidonic acid cascade resulting in derange-
ment of astrocytes-glial-neuronal communications [33]. In
addition to increased prostaglandin formation, TNF-alpha
increases the expression of proteinase-activated receptor-2
(PAR-2)whichisresponsibleforcellsurvival[34].Micelack-
ing PAR-2 are more susceptible to Tat-induced toxicity than
wild-type [34] .S D F - 1p r o m o t e sc e l ls u r v i v a l ,w h i c hi sn o t
what would be expected considering that SDF-1 and gp120
are both agonists at the CXCR4 receptor. This discrepancy
could be explained by diﬀerential eﬀects on the p53 sys-
tem. Stimulation of CXCR4 by gp120 stimulates p53 and
increases the phosphorylation of Apaf-1 (proapoptotic) in
neurons [35]. In addition, gp120 regulates the phosphory-
lation of p53 and regulates the expression of MDM-2 and
p21 [35]. These eﬀects are reversed by the p53-inhibitor
piﬁthrin-alpha. Contrary to these ﬁndings, SDF-1 stimulates
the acetylation of p53 and promotes the production p21.David R. Wallace 3
Therefore, stimulation of the CXCR4 receptor could result
in activation of diﬀerent p53 targets dependent on the stim-
ulating ligand, which will determine whether activation of
CXCR4 exerts a positive or negative inﬂuence on neurons.
Collectively, these data demonstrate the importance of as-
trocytes/microglia in the pathogenesis of HIV-related neu-
rotoxicity. Early hypotheses focused on the involvement of
glutamate as an integral component of HIV neurotoxicity.
Although glutamate is a major toxin involved in neuronal
death, it is now apparent that the CXCR4 receptor medi-
ates cell death via non-glutamate mechanisms [36]. Investi-
gation into the development of CXCR4 antagonists, in con-
junction with NMDA antagonists, would oﬀer better protec-
tion against gp120-induced cellular death.
GLUTAMATE AND EXCITATORY AMINO ACIDS
As discussed in the previous section, CXCR4 receptors ap-
pear to have a major role in the development of HIV-related
neurotoxicity. Another component of this toxicity is the
role of glutamate in cellular death. The toxic component
secreted from HIV-1infected mononuclear phagocytes has
been characterized as being a glutamate [37]. Some of the
earliest studies demonstrated the addition of the N-methyl-
D-aspartate (NMDA-) receptor antagonist memantine [38].
The addition of memantine not only increased the viabil-
ity of neurons, but improved the dendritic arborization and
synaptic density. The toxic eﬀect is due to both the stim-
ulation of NMDA receptors and the subsequent elevation
in intracellular calcium. Coadministration of D-2-amino-5-
phosphonopentanoic acid (APV) or MK-801 (both NMDA
receptor antagonists) or removal of calcium from the culture
media all decrease cell death associated with gp120 exposure
[39]. One hypothesis for gp120 eﬀects on glutamate home-
ostasis involves the attenuation of glutamate uptake, and
concomitant increase in glutamate release [40]. Both gp120
and Tat have been postulated to work through a glutamate-
mediated mechanism. Nath et al [11] demonstrated that
coadministration of both gp120 and Tat exerted a synergis-
tic potentiation of toxicity in monkeys. The concentrations
of both gp120 and Tat were at subtoxic concentrations, yet
the addition of the two proteins together resulted in a signiﬁ-
cant amount of cell death. To determine if these eﬀects could
be mediated by glutamate, the addition of memantine com-
pletely blocked the toxicity exerted by the gp120/Tat com-
bination [11]. The toxic eﬀects of Tat alone have also been
linked to glutamatergic eﬀects. Exposure of rat cortical neu-
ronal cultures to low (nanomolar) concentrations of Tat or
gp120 (picomolar) increases the uptake of calcium into neu-
rons and eventually leads to cell death [41, 42]. Coadmin-
istration with the glutamate antagonists completely blocked
the observed increase in 45Ca inﬂux and cell death [41, 42].
Administration of non-glutamate drugs had no eﬀect on cal-
cium inﬂux or cellular death. In addition to the reports of di-
rect alterations in glutamate homeostasis leading to cellular
dysfunction,otherendogenous glutamateagonistshavebeen
shown to be elevated in HIV infected individuals. One com-
pound that has been shown to be elevated in HIV-patients
is quinolinic acid. Activated macrophages produce quino-
linic acid and this toxin has been implicated in a variety of
neurological disorders. Macrophages exposed to Tat signiﬁ-
cantly increased their production of quinolinic acid, which
correlated with an increase in indolamine 2,3-dioxygenase
induction [43]. Interestingly, production of quinolinic acid
occurs as part of the kynurenic acid pathway. Kynurenic acid
is neuroprotective and functions as a glutamate antagonist
[44]. A shift of the synthesis pathway favoring quinolinic
acid results in neurotoxicity. Recent studies have added new
insight into the mechanisms of HIV neurotoxicity involv-
ing the glutamate system [45, 46]. Not only does glutamate
function through direct excitotoxic mechanisms by stimu-
lating NMDA receptors, but also glutamate can induce the
production of free radicals by inhibiting the uptake of cys-
tine uptake and thus reducing the formation of glutathione
[45]. Activated microglia express the glutamate transporter
EAAT-1 and the density of this transporter increases with
progression through the disease process. It would be sus-
pected that this would provide protection against toxicity by
increasing glutamate uptake and may in fact provide protec-
tion for a period of time. Later in the disease, when cogni-
tive/motor deﬁcits are more apparent and dementia begins,
dysfunction of activated microglia could play a role in the
neuronal apoptosis and death normally observed later in the
disease [45]. Although it has been accepted that Tat toxic-
ity involves a glutamate component, the exact mechanism
by which this occurs has not been elucidated. Chandra et al
[46]demonstratedthatTatreleasesZn2+ fromitsbindingsite
on the NMDA receptor. When Zn2+ is bound to the NMDA
receptor, the receptor has reduced capacity to conduct Ca2+
through its channel. When Zn2+ is removed, even at neuro-
protective concentrations, the NMDA receptor is activated;
there is an increase in Ca2+ inﬂux resulting in increased ac-
tivity of an intracellular cascade leading to cellular death.
APOPTOSIS, CALCIUM, AND NITRIC OXIDE
As previously discussed, microglia involvement in HIV-
related neurotoxicity involves oxidative stress, alterations in
calcium homeostasis, activation of NMDA receptors, and
apoptosis. Stimulation of NMDA receptors result in an in-
ﬂux of extracellular calcium. Elevations in intracellular cal-
ciumwouldactivatenitricoxidesynthaseinneurons(nNOS,
or NOS-1). Increases in nitric oxide can react with cellular
superoxide forming the damaging peroxynitrite. This is fur-
ther compounded by the contribution of nitric oxide from
microglia which is inducible (iNOS or NOS-2). The involve-
ment of nitric oxide in a variety of neurodegenerative dis-
eases can be robust [47]. Polazzi et al [12] reported that
Tat acts at the level of the iNOS gene to increase produc-
tion of nitric oxide from activated microglia. Therefore, Tat
does not act simply to increase the production of nitric ox-
ide, but at the genomic level to induce the production of
iNOS and interacts with NF-κB and interferon-gamma to
potentiate the damage resulting from the nitric oxide that
is produced [12]. This cycle could potentially form a “feed-
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leads to alterations in calcium homeostasis, increases in ni-
tric oxide formation, neuronal death, microglia activation,
and additional nitric oxide being induced from the activated
microglia [48]. Inhibitors of the NMDA receptor (MK-801)
or iNOS (1400W) all reduced gp120-induced neurotoxicity
[48].TheseﬁndingssuggestanimportantroleofiNOSinthe
development of HIV-related neurotoxicity. Changes in intra-
cellular calcium regulation may involve Na+/H+ exchangers
and L-type calcium channels [41]. Addition of amiloride at-
tenuatedtheintracellularriseinintracellularcalciuminboth
neurons and astrocytes. Blockade of L-type calcium channels
with nimodipine, diltiazem, and CdCl2 +N i C l 2 also signiﬁ-
cantly decreased the rise in intracellular calcium in neurons,
with no eﬀect in astrocytes. This diﬀerential eﬀect on neu-
rons and astrocytes could aﬀord protection against calcium-
related toxicity if appropriate drugs are used to distinguish
between neuron and astrocytes actions. One possible mech-
anism for this increase in intracellular calcium involves Tat
modulation of phosphoinositide (PI) turnover [9]. Exposure
of cultured fetal neurons to Tat resulted in elevated intracel-
lular calcium that is attenuated by antagonizing the eﬀects of
inositol 1,4,5-triphosphate on releasing calcium from intra-
cellularstores.Speciﬁcally,Tatfunctionsthroughapertussis-
toxinsensitivephospholipaseCmechanismtoincreaseintra-
cellular calcium leading to glutamate receptor-mediated cal-
cium inﬂux and subsequent dysregulation of calcium home-
ostasis [9].
Multiple mechanisms can lead to cellular apoptosis. It is
accepted that both Tat and gp120 exposures will elicit sig-
niﬁcant cellular damage and death, but the apoptotic mech-
anisms diﬀer between the two proteins. Both gp120 and
Tat have been shown to induce apoptosis in neuronal cul-
ture. TGF-beta1 reverses the alterations observed in calcium
homeostasis and reduces the number of neuronal cells dy-
ing from apoptotic cell death following exposure to gp120
[49]. TNF-alpha augments the eﬀects of Tat on apoptosis
which seem to be mediated in part by oxidative stress [50].
Administration of antioxidants will partially reverse the ef-
fects of Tat, yet a component exists which is not due to ox-
idative stress. Using HIV-1 isolates, cell lines which overex-
press Bcl-2 or Bcl-xL are protected from damage whereas the
wild-type cells are signiﬁcantly compromised [51]. Addition
of a Bcl-2 antagonist to the overexpressing cells completely
reversed the neuroprotection. Collectively, the Bcl-2 path-
way is an important pathway for the pathogenesis of HIV-
related neurodegeneration, and modulation of this pathway
could aﬀord protections against neuronal damage. Another
pathway with importance for HIV neurodegeneration in-
volves TNF-alpha and the TNF-related apoptosis-inducing
ligand(TRAIL).InHIVinfection, humanmonocyte-derived
macrophages exhibit an increase in TRAIL levels and
these cells are associated with neurons which are caspase-
3p o s i t i v e[ 52]. Analysis of speciﬁc protein actions has
demonstrated that gp120 works in part through enhance-
ment of COX-2 expression and activation of interleukin-
1 converting enzyme (caspase-1). Antagonists of caspase-
1 activity, acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-
YVAD-CMK) and t-butooxycarbonyl-L-aspartic acid benzyl
ester-chloromethylketone (Boc-Asp-(OBzl)-CMK) block the
release of interleukin-1beta and attenuate apoptosis [53].
Blockade of the inducible form of COX-2 with NS-398 also
prevents the rise in cellular apoptosis [53]. Intraventricular
administration of gp120 for up to 7 days resulted in an eleva-
tion in the expression of caspase-3 in rat brain [54]. Singh et
al [55] expanded these ﬁndings to conﬁrm those of Acquas
et al [54] that demonstrated gp120 activation of caspase-3,
but extended them to include the actions of Tat which ap-
peared to promote apoptosis via an endonuclease G mecha-
nism. The caspase inhibitor Z-DEVD-FMK signiﬁcantly re-
duces gp120-induced elevations in caspase-3, but had no sig-
niﬁcant eﬀect on Tat toxicity. These ﬁndings are the ﬁrst to
suggest that although both gp120 and Tat elicit robust neu-




Postmenopausal women who are infected with HIV are at
risk for experiencing dementia and Parkinson’s-like symp-
toms associated with low levels of estrogen [56] leading to
speculation that estrogen may attenuate the development
of these debilitating symptoms [57]. 17β-estradiol (E2)has
been generally observed to be neuroprotective in cell culture
[58, 59]. A potential mechanism for E2 protection may be
the phenolic A ring, which would act as a direct free radi-
cal scavenger [60]. The concept of neuroprotection by E2 has
expanded beyond the realm of simple steroid-receptor inter-
actions to include interactions with unidentiﬁed cell-surface
receptors and direct modulation of neurotransmitter func-
tion [58, 59]. Potential exists for direct eﬀects of E2 as a free
radical scavenger, interactions with cell-surface receptors, or
with its nuclear binding site. From these studies, the latter
appears to be unlikely since nuclear eﬀect would commonly
occur over hours or days. It is clear that E2 aﬀords some level
of neuroprotection in all culture models, and this protection
is dependent on a complex system of interactions from the
extracellular to the nuclear space.
Collectively,previousreportshavehelpedtopartiallyelu-
cidatethemechanismsofTatandgp120toxicity.Recentwork
has indicated that E2 may slow the transmission of HIV [61],
protect against the synergistic toxicity of Tat and gp120 [62],
reduce Tat-induced inﬂammation in endothelial cells [63],
and may prevent neuronal death in the presence of HIV-1
protease [64]. The synergist toxicity following gp120 and Tat
exposure can be extended to synergistic toxic eﬀects of co-
caine. Subtoxic concentrations of gp120 and Tat, plus phys-
iologically relevant concentrations of cocaine, resulted in a
signiﬁcant increase in cell death [65]. This eﬀect is blocked
in the presence of E2,b u tn o t1 7 α-E2.P r o g e s t e r o n ea ﬀorded
minimal protection, yet surprisingly, testosterone exhibited
protection on the level of E2 [65]. The eﬀects of both E2 and
testosterone were reversed by ICI-182,780, a selective estro-
gen antagonist, suggesting interactions with the cell-surface
E2 receptors. Not only does E2 protect against oxidative cellDavid R. Wallace 5
death, but also evidence suggests that it prevents apoptosis,
through both a Bcl/Bax mechanism and interleukin-1beta
[24, 66]. This inhibition is reversed by both ICI-182,780 and
tamoxifen, E2 antagonists. Further work is needed on this
topic to determine the eﬃcacy of E2 neuroprotection with
regard to HIV neurotoxicity [67].
Glucocorticoids
The ability of glucocorticoids to potentiate HIV neurotoxi-
city has long been known, but the mechanisms of this ac-
tion are poorly understood. Synthetic glucocorticoids such
as prednisone and dexamethasone potentiate the eﬀects of
gp120onintracellularcalciumconcentration[68,69].Thisis
particularly deleterious considering that these synthetic glu-
cocorticoids are routinely used to treat Pneumocystis carinii
pneumonia, which is commonly observed in AIDS patients.
A possible mechanism for this action is via reduction in en-
ergy (ATP) levels which reduces mitochondrial membrane
potential and promotion of extracellular calcium increases.
Energy supplementation has been shown to ameliorate these
eﬀects of glucocorticoids [68] .T h e s es t u d i e sh a v eb e e nr e p l i -
cated in vivo using physiological concentrations of cortisol,
resembling concentrations observed during stress with sim-
ilar outcomes, increased mobilization of intracellular cal-
cium, and increased depletion of ATP [70]. Concentrations
of glucocorticoids and gp120, which are nontoxic indepen-
dently,causesigniﬁcanttoxicitywhencoadministeredinstri-
atal cultures [69]. Administration of gp120 alone results
in signiﬁcant increases in reactive oxygen species, whereas
coadministration with cortisol increases the amount of lipid
peroxidation [71]. It is clear that glucocorticoids exacerbate
HIV,andgp120,toxicitybypotentiatingincreasesinintracel-
lular calcium and reducing cellular ATP levels. When com-
bined, these eﬀects predispose the cell to oxidative damage
and death.
STRIATAL TOXICITY, DOPAMINE, AND DEMENTIA
HIV dementia is a subcortical dementia associated with dys-
function in the basal ganglia [72]. Currently, there are mul-
tiple HIV proteins that have been reported to exert neu-
rotoxic eﬀects. Several groups have demonstrated the pres-
ence of Tat protein in brains of patients with HIV encephali-
tis by immunostaining [73, 74]. Additionally, mRNA lev-
els for Tat are also elevated in brain tissue of patients with
HIV dementia [73]. Once released, Tat and gp120 have been
shown to exert toxicity through an oxidative stress pathway
[4–6, 75]. One neurological system that is involved in gp120-
and Tat-induced neurotoxicity is the dopaminergic system.
Patients develop symptoms of dopamine deﬁciency and ex-
hibit heightened sensitivity to dopaminergic selective drugs
as well as psychostimulants which act on dopaminergic neu-
rons in the basal ganglia [76]. Other neurotransmitter sys-
temsthatinteractwiththedopaminergicsystem,suchasglu-
tamatergicandopioid[77],alsoincreasethesensitivityofthe
basal ganglia to the neurotoxic properties of gp120 and Tat.
Therefore, the basal ganglia and the dopaminergic system
would be a likely target for the development of therapeu-
tic agents to attenuate or prevent the development of HIV-
associated dementia.
Administration of gp120 to striatal cell cultures elic-
its a toxicity that is reversed by coadministration of a glu-
tamate antagonist [1]. Toxicity of Tat to striatal neurons
is due, in part, to direct actions on the neuron which is
not subject to desensitization [3]. The dementia that has
been observed in HIV patients only occurs in about 20% of
all infected people. Comparison of brain extracts from de-
mented versus non-demented patients revealed that super-
natants from demented patients showed signiﬁcantly greater
toxicity compared to supernatants obtained from nonde-
mented patients [78]. One underlying mechanism for HIV-
related dementia and Parkinson-like symptoms could be loss
of dopamine transporters/function following gp120 and Tat
exposure. Recently, Wang et al [79] reported that patients
suﬀering from HIV-associated dementia exhibited a signif-
icant 13%–20% reduction in dopamine transporter density
compared to seronegative controls. This study was the ﬁrst
to demonstrate HIV-induced damage to dopaminergic ter-
minals in humans, which was inversely related to viral load
(load increases, transporter density decreases). Additional
studiesareneededtofurtherelucidatethesemechanismsand
oﬀer insight into possible therapeutic interventions to pre-
vent/attenuation HIV-associated neurotoxicity to dopamine
neurons.
POTENTIAL THERAPEUTIC INTERVENTIONS
Currently, there are no therapeutic interventions which can
be used to attenuate the development of HIV neurotoxic-
ity and/or dementia. Based on the data that has been dis-
cussed, logical choices would be ligands which block some
of the mechanisms associated with gp120 and Tat toxicity.
ThiscouldincludeantagonizingNMDAglutamatereceptors,
blocking the intracellular rise in calcium, inhibition of NOS,
or blocking the eﬀects of microglia/chemokines. One of the
ﬁrst avenues pursued was antagonism of the NMDA recep-
tor.AlowconcentrationofNMDA,plusarachidonicaciden-
hances toxicity in neuronal culture. It is possible that gp120
activates phospholipase A2 to increase arachidonic acid re-
lease, which then sensitizes the NMDA receptor to the ac-
tions of glutamate. This eﬀect is reversed by memantine, an
NMDA receptor antagonist [80, 81]. Memantine is currently
clinically used to treat spasticity and Parkinson’s disease and
may provide therapeutic relief of some of the symptoms of
HIV neurotoxicity. Further work is warranted to more com-
pletely elucidate the function of memantine in the CNS and
determine its usefulness in treating HIV neurotoxicity. A
drawback to memantine use is that it will only be eﬀective if
used in a prophylactic manner. After neuronal death occurs,
and the onset of dementia is apparent, memantine would
have little therapeutic usefulness other than to slow the pro-
gression of dementia.
Opioid compounds have yielded the mixed results when
attempting to determine their interaction with the gp120 or
the Tat. Compounds which would normally be considered6 Journal of Biomedicine and Biotechnology
mu-preferring have been shown to potentiate the toxicity
of gp120 and Tat [25]. Conversely, other kappa- and delta-
preferring opioid and nonopioid analgesic agents have been
shown to be protective. The nonopioid compound, ﬂupir-
tine, produces analgesia, but also possesses anticonvulsant
andmuscle-relaxantpropertiesandhasbeenshowntobecy-
toprotective against gp120-induced toxicity [80]. The kappa-
preferring agonist, U50,488, suppresses microglia release of
quinolinic acid [82]. Suppression of quinolinic acid release
will decrease stimulation of NMDA receptors and conse-
quently reduce excitotoxicity in neurons. We have shown
that the peptidergic delta agonist, DPDPE, reduces oxida-
tive stress in SK-N-SH cells exposed to Tat [83]. Our results
also extend to the nonpeptidergic agonist, SNC-80, and the
eﬀects of both agonists are reversed by delta-preferring an-
tagonists, suggesting a receptor-mediated mechanism for in-
hibition of oxidative stress [83]. Interestingly, opioids which
are abused (morphine, heroin, and their derivatives) act pri-
marily at the mu-subtype, which is the subtype primarily re-
sponsible for synergistic toxicity with gp120 and Tat. Agents
which act at kappa- and delta-opioid receptors may provide
viableanalgesicoptionsforindividualsthatareHIVinfected.
Another area that has garnered a great deal of interest in
the last decade has been the eﬀects of steroids on the neu-
rotoxicity of HIV proteins. It has become clear that hor-
mones released in response to stress, namely cortisol, po-
tentiate the toxicity of gp120 and Tat [69, 70]. Intermedi-
ate (prednisone) and long-acting (dexamethasone) gluco-
corticoids are often prescribed for respiratory-symptoms-
associated opportunistic diseases associated with HIV which
could compound HIV-related neurodegeneration. More in-
terest has been given to the protective eﬀects of estrogen. We
have shown that estradiol reduces the oxidative stress elicited
by gp120 and Tat in SK-N-SH cells and this eﬀect is reversed
by the estrogen antagonist ICI-182,780 [84]. This work sup-
ported previous reports that estradiol attenuates the toxic-
ity following HIV-1 protease administration [64], gp120 ad-
ministration [85, 86], or coadministration of gp120 and Tat
[62]. There have been mixed results concerning the eﬀects
of other sexsteroids such as progesterone, testosterone, and
their derivatives. It appears that whether these hormones are
protective or potentiating depends on the assay system that
is being utilized and the manipulations that are used to op-
timize the assay. Further work on the eﬀects is necessary to
fully understand its protective potential in HIV model sys-
tems. Questions that must be asked are (1) are the eﬀects
of estradiol selective for estradiol, or can other “estrogens”
elicit the same eﬀect, and (2) are estradiol eﬀects mediated
by cell-surface receptors, intracellular receptors, or possible
due to the structural nature of estradiol. Areas of current
research that appear to be yielding exciting results are the
use of selective-estrogen receptor modulators (SERMs) and
the use of plant-derived estrogens. Early studies have shown
that administration of some of these compounds can pre-
vent, or attenuate, HIV protein-induced toxicity without the
side eﬀects associated with estrogen, such as promotion of
estrogen-dependent tumors in females or feminization of
males (unpublished observations).
Awidearrayofotherapproacheshasbeenusedtotryand
prevent the pathogenesis of HIV-related neurodegeneration
and dementia. One compound that has yielded interesting
results is CPI-1189 in the treatment of HIV-related demen-
tia. CPI-1189 works through an unknown mechanism, but
appears to ameliorate TNF-alpha toxicity by increasing ac-
tivation of ERK-MAP kinase [87]. CPI-1189 also attenuates
culture toxicity in the presence of quinolinic acid and gp120
[87]. Excitement about CPI-1189 has waned after a more re-
cent clinical trial has indicated that CPI-1189 is well toler-
ated, but did not demonstrate a signiﬁcant improvement in
neuropsychological measures[88]. Inhibition of matrix met-
alloproteinase with prinomastat reduced neuronal toxicity
following exposure to supernatants from brain-derived Tat
sequences obtained from demented patients [89]. The hy-
pothesis put forth by Johnston et al [89] was that the par-
ticular Tat sequence from demented patients resulting in a
higher level of toxicity due to induction of matrix metal-
loproteinases. Prophylactic treatment with lithium has also
been postulated to be neuroprotective [90]. Pretreatment or
coadministration of lithium to neuronal cultures exposed to
gp120 was protected via a phosphatidylinositol 3-kinase/Akt
pathway, but treatment following gp120 exposure was in-
eﬀective [90]. Targeting oxidative damage is another thera-
peutic avenue that has been explored. Compounds such as
L-deprenyl, didox, imidate, diosgenin, and ebselen all pre-
vented oxidative damage following exposure to CSF from
HIV demented patients [91]. Human lipidated apoE3 has
also been shown to protect neurons from Tat-induced tox-
icity via prevents of Tat-induced oxidative stress [92, 93].
Also Tat and apoE compete for the same binding site, re-
sulting in increased extracellular Tat; the ability for apoE to
prevent Tat-induced oxidative stress may outweigh the in-
crease in extracellular Tat. More investigation into this ef-
fect would be warranted prior to making any deﬁnitive con-
clusions regarding the eﬀectiveness of apoE. Involvement of
chemokines, and in particular the CXCR4 and CCR5 recep-
tors, in HIV-neurotoxicity and dementia has been demon-
strated by many investigators. One hypothesis put forth in-
volves the blockade of these receptors, leading to subsequent
reductions in toxicity. Use of a novel CXCR4 antagonist,
neomycin B hexa-arginine, has been shown to eﬀectively
cross the blood-brain barrier and reduce gp120-induced tox-
icity through a CXCR4-mediated mechanism [27].
Collectively, there appears to be no deﬁnitive therapeutic
treatment for HIV-neurodegeneration and dementia. Some
of the above compounds, such as the estrogenic compounds
and the CXCR4 antagonist, neomycin B hexa-arginine, have
shownsomepromise.Useofbrain-derivedneurotrophicfac-
tor (BDNF) has yielded favorable results, although delivery
o fap e p t i d ei n t ot h eb r a i no ﬀers some challenges [94]. A
great deal of additional work is still necessary to determine
the true eﬀectiveness of any of these therapeutic approaches.
SUMMARY AND CONCLUSIONS
It is clear from the literature and ongoing studies that con-


















Scheme 1: Schematic of various into HIV neurotoxicity and the major factor involved.Although not an inclusive list, these are the major factors
in the pathogenesis of HIV neurotoxicity and the development of dementia. The surrounding circles are not meant to imply that each factor
is exclusive of other factors since considerable overlap exists between each of the components.
mechanisms of HIV neurotoxicity and the development of
HIV-related dementia. It is also apparent that the devel-
opment of therapeutically useful drugs will be delayed due
to the complexity of the systems involved with HIV, and
gp120/Tat in particular, toxicity. In Scheme 1,f a c t o r si m -
plicated in HIV neurotoxicity are depicted demonstrating
the complexity of mechanisms underlying HIV neurotoxi-
city. Each of the surrounding circles also represent current
avenues being pursued in the development of clinically rele-
vant compounds to attenuate or prevent the progression of
HIV neurotoxicity and dementia.
In sum, interest in elucidating the toxicity cascades for
gp120 and Tat toxicity is great. Understanding these cas-
cades is tantamount to developing therapeutic agents which
could attenuate or prevent the neuronal degeneration asso-
ciated with late-stage HIV infection. Agents with eﬀects on
multiple cascades are the most likely agents to provide re-
lief from the progression of neuronal degeneration and may
very likely come from sources not yet examined. An example
couldbetheeﬀectsoflithiumongp120toxicityaspreviously
reported. Fully understanding the diﬀerences between indi-
viduals who are demented and those who are not will add
signiﬁcant amounts of information to our knowledge base.
If the next decade has even greater productivity than the last,
signiﬁcant and robust advancements can be achieved.
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